5H-环戊二烯并[d]嘧啶 | 270-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5H-环戊二烯并[d]嘧啶
• 英文名称: 5h-Cyclopenta[d]pyrimidine
• CAS: 270-98-4
• 化学式: C₇H₆N₂
• 分子量: 118.14
• InChiKey: FBBAXRAVJZOJGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Sakagami Masahiro

  公开号：US20110028468A1

  公开（公告）日：2011-02-03

  This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is substituted or unsubstituted alkyl or the like, R 2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R 3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R 4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

  这项发明提供了式(I)的化合物： 其药学上可接受的盐或溶剂化合物， 其中 R1为取代或未取代的烷基或类似物， R2为氢或取代或未取代的烷基， 环A为单环或双环芳香杂环， R3为取代或未取代的芳基，取代或未取代的杂芳基或取代或未取代的杂环， R4为卤素，氰基，取代或未取代的烷基，取代或未取代的环烷基或类似物， m为0到2之间的整数， n为0到5之间的整数， R为卤素，氧代，氰基，硝基，取代或未取代的烷基或类似物，以及 p为0到2之间的整数 作为具有NPY Y5拮抗活性的新化合物。
• ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20140315961A1

  公开（公告）日：2014-10-23

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了式（I）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制精氨酸甲基转移酶活性是有用的。还描述了利用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20170157120A1

  公开（公告）日：2017-06-08

  Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

  描述了对蛋白激酶活性有影响的化合物，以及制备和使用这些化合物来治疗与蛋白激酶异常活性相关的疾病和症状的方法。
• PRMT1 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20140288140A1

  公开（公告）日：2014-09-25

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.

  本文描述了式（I）的化合物，其药用盐以及药物组成物。本文描述的化合物可用于抑制PRMT1活性。还描述了使用这些化合物治疗PRMT1介导的疾病的方法。